CStone Pharmaceuticals (2616.HK)
| Previous Close | 0.880 |
| Open | 0.890 |
| Bid | 1.080 x 0 |
| Ask | 1.090 x 0 |
| Day's Range | 0.870 - 1.150 |
| 52 Week Range | 0.800 - 3.270 |
| Volume | |
| Avg. Volume | 2,542,934 |
| Market Cap | 1.39B |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.310 |
| Earnings Date | Mar 27, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.56 |
PR NewswireCStone Pharmaceuticals Reports 2023 Annual Results and Business Updates
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.
PR NewswireCStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl
PR NewswireCStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Servier, a global independent pharmaceutical group, today announced an agreement whereby Servier acquires from CStone the exclusive rights to develop and commercialize TIBSOVO® (ivosidenib tablets) in Greater China and Singapore.
